LY3819469 (End-Stage Renal Disease) for Kidney Failure

Nucleus Networks, Saint Paul, MN
Kidney Failure+1 More ConditionsLY3819469 - Drug
Eligibility
18 - 85
All Sexes
What conditions do you have?
Select

Study Summary

This trial looks at the effects of a drug called LY3819469 on people with and without kidney problems. It'll assess safety, levels in the bloodstream, and how long it takes to get rid of. Trial length up to 17 weeks.

Eligible Conditions
  • Kidney Failure
  • Healthy Subjects

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1

Similar Trials

1
Arm I (tranexamic acid)
1
Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII
1
Mocetinostat

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: Predose up to 85 days postdose

Day 85
PK: Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3819469
PK: Maximum observed concentration (Cmax) of LY3819469
Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to last time point (AUC0-tlast) of LY3819469

Trial Safety

Phase-Based Safety

1 of 3

Similar Trials

1
Arm I (tranexamic acid)
1
Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII
1
Mocetinostat

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

3 Treatment Groups

LY3819469 (End-Stage Renal Disease)
1 of 3
LY3819469 (Control)
1 of 3
LY3819469 (Severe Renal Impairment)
1 of 3

Experimental Treatment

28 Total Participants · 3 Treatment Groups

Primary Treatment: LY3819469 (End-Stage Renal Disease) · No Placebo Group · Phase 1

LY3819469 (End-Stage Renal Disease)
Drug
Experimental Group · 1 Intervention: LY3819469 · Intervention Types: Drug
LY3819469 (Control)
Drug
Experimental Group · 1 Intervention: LY3819469 · Intervention Types: Drug
LY3819469 (Severe Renal Impairment)
Drug
Experimental Group · 1 Intervention: LY3819469 · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3819469
2021
Completed Phase 1
~70

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: predose up to 85 days postdose

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,499 Previous Clinical Trials
3,155,327 Total Patients Enrolled
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Study DirectorEli Lilly and Company
1,280 Previous Clinical Trials
381,777 Total Patients Enrolled

Eligibility Criteria

Age 18 - 85 · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

Is enrollment in this research project still open?

"Based on the clinicaltrials.gov data, this medical trial is no longer enrolling patients. It was initially posted on April 25th 2023 and its last update came a day prior to that date. Nevertheless, there are 954 other trials currently accepting participants at the moment." - Anonymous Online Contributor

Unverified Answer

Is this trial open to participants under the age of 25?

"This trial's eligibility criteria require that all participants are between 18 to 85 years old. For those below and above this range, there are 62 trials for minors and 510 studies specifically targeting seniors." - Anonymous Online Contributor

Unverified Answer

Has FDA clearance been granted for LY3819469 (Control)?

"Our safety rating for the control drug LY3819469 is 1 due to its Phase 1 status, which means there are limited data affirming both its efficacy and security." - Anonymous Online Contributor

Unverified Answer

Who meets the qualifications for enrollment in this experiment?

"This medical trial is open to patients aged 18-85 with kidney failure. Currently, 28 individuals are being sought after for enrollment." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top